Characterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study

dc.authorscopusidMeral Beksac / 56924887200
dc.authorwosidMeral Beksac / D-6411-2013
dc.contributor.authorHang, Quach
dc.contributor.authorDimopoulos, Meletios
dc.contributor.authorBeksac, Meral
dc.contributor.authorPour, Ludek
dc.contributor.authorDelimpasi, Sosana
dc.contributor.authorVorobyev, Vladimir
dc.date.accessioned2025-06-03T13:41:59Z
dc.date.available2025-06-03T13:41:59Z
dc.date.issued2024
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, İSÜ Hastaneleri
dc.description.abstractCharacterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study
dc.identifier.citationQuach, H., Dimopoulos, M., Beksac, M., Pour, L., Delimpasi, S., Vorobyev, V., ... & Trudel, S. (2024). Characterization and Management of Ocular Events in Patients Treated with Belantamab Mafodotin Plus Pomalidomide and Dexamethasone in the DREAMM-8 Study. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 24, S273-S273.
dc.identifier.endpage273
dc.identifier.issn2152-2650
dc.identifier.issn2152-2669
dc.identifier.startpage273
dc.identifier.urihttps://hdl.handle.net/20.500.12713/7287
dc.identifier.volume24
dc.identifier.wosWOS:001325737900475
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.institutionauthorBeksac, Meral
dc.institutionauthoridMeral Beksac / 0000-0003-1797-8657
dc.language.isoen
dc.publisherCIG media group
dc.relation.ispartofClinical lymphoma, myeloma and leukemia
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.titleCharacterization and management of ocular events in patients treated with belantamab mafodotin plus pomalidomide and dexamethasone in the DREAMM-8 study
dc.typeOther

Dosyalar

Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.17 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama: